A detailed history of Israel Englander (Millennium Management LLC) transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 7,800 shares of APLS stock, worth $216,450. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,800
Previous 205,911 96.21%
Holding current value
$216,450
Previous $7.9 Million 97.16%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$28.84 - $41.15 $3.71 Million - $5.29 Million
-128,525 Reduced 62.42%
77,386 $2.23 Million
Q2 2024

Aug 14, 2024

SELL
$38.07 - $59.71 $22.1 Million - $34.6 Million
-579,485 Reduced 73.78%
205,911 $7.9 Million
Q1 2024

May 15, 2024

BUY
$55.39 - $72.47 $42.8 Million - $56 Million
772,869 Added 6169.63%
785,396 $46.2 Million
Q4 2023

Feb 14, 2024

SELL
$37.14 - $64.82 $33.7 Million - $58.7 Million
-906,284 Reduced 98.64%
12,527 $749,000
Q2 2023

Aug 14, 2023

BUY
$76.68 - $93.31 $28.4 Million - $34.6 Million
370,610 Added 67.6%
918,811 $83.7 Million
Q1 2023

May 15, 2023

BUY
$46.59 - $66.96 $24.6 Million - $35.4 Million
528,565 Added 2691.82%
548,201 $36.2 Million
Q4 2022

Feb 14, 2023

SELL
$43.24 - $61.04 $10.3 Million - $14.5 Million
-238,233 Reduced 92.39%
19,636 $1.02 Million
Q3 2022

Nov 14, 2022

BUY
$44.76 - $69.66 $11.5 Million - $18 Million
257,869 New
257,869 $17.6 Million
Q1 2022

May 16, 2022

SELL
$35.46 - $54.12 $8.92 Million - $13.6 Million
-251,497 Reduced 80.61%
60,505 $3.07 Million
Q4 2021

Feb 14, 2022

SELL
$30.74 - $49.16 $2.87 Million - $4.59 Million
-93,380 Reduced 23.04%
312,002 $14.8 Million
Q3 2021

Nov 15, 2021

BUY
$31.4 - $69.84 $7.75 Million - $17.2 Million
246,811 Added 155.65%
405,382 $13.4 Million
Q1 2021

May 17, 2021

SELL
$40.8 - $57.39 $3.39 Million - $4.77 Million
-83,143 Reduced 34.4%
158,571 $6.8 Million
Q4 2020

Feb 16, 2021

SELL
$30.79 - $57.2 $20.8 Million - $38.6 Million
-674,989 Reduced 73.63%
241,714 $13.8 Million
Q3 2020

Nov 16, 2020

SELL
$25.89 - $33.65 $4.1 Million - $5.34 Million
-158,547 Reduced 14.75%
916,703 $27.7 Million
Q2 2020

Aug 14, 2020

SELL
$24.8 - $38.49 $7 Million - $10.9 Million
-282,336 Reduced 20.8%
1,075,250 $35.1 Million
Q1 2020

May 14, 2020

BUY
$17.91 - $44.33 $13.9 Million - $34.4 Million
774,980 Added 133.02%
1,357,586 $36.4 Million
Q4 2019

Feb 14, 2020

SELL
$22.1 - $30.8 $47 Million - $65.6 Million
-2,128,655 Reduced 78.51%
582,606 $17.8 Million
Q3 2019

Nov 14, 2019

BUY
$24.09 - $32.18 $16.1 Million - $21.5 Million
667,337 Added 32.65%
2,711,261 $65.3 Million
Q2 2019

Aug 15, 2019

BUY
$18.0 - $25.34 $18.2 Million - $25.6 Million
1,010,730 Added 97.83%
2,043,924 $51.8 Million
Q2 2019

Aug 14, 2019

SELL
$18.0 - $25.34 $16.1 Million - $22.6 Million
-893,372 Reduced 46.37%
1,033,194 $14.2 Million
Q1 2019

May 14, 2019

BUY
$12.81 - $19.82 $9.53 Million - $14.7 Million
744,181 Added 62.94%
1,926,566 $37.6 Million
Q4 2018

Feb 14, 2019

BUY
$11.47 - $18.71 $863,415 - $1.41 Million
75,276 Added 6.8%
1,182,385 $15.6 Million
Q3 2018

Nov 14, 2018

BUY
$16.57 - $21.03 $3.54 Million - $4.49 Million
213,649 Added 23.91%
1,107,109 $19.7 Million
Q2 2018

Aug 14, 2018

BUY
$19.63 - $30.0 $17.5 Million - $26.8 Million
893,460 New
893,460 $19.7 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.05B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.